Immunocore to present at upcoming investor conferences

Rhea-AI Summary

Immunocore (Nasdaq: IMCR) announced management will present at two investor conferences in November 2025: a Guggenheim 2nd Annual Healthcare Innovation Conference fireside chat on Tuesday, November 11, 2025 at 3:00 p.m. EST, and a Jefferies London Healthcare Conference fireside chat on Wednesday, November 19, 2025 at 3:30 p.m. GMT.

Where relevant, presentations will be webcast live and available under Investors > Events & Presentations on Immunocore's website, with replays posted for a limited time.

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, November 10, 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced management will participate at the following conferences in November.

        Guggenheim 2^nd Annual Healthcare Innovation Conference
        Fireside Chat: Tuesday, November 11, 2025, at 3:00 p.m. EST

        Jefferies London Healthcare Conference
        Fireside Chat: Wednesday, November 19, 2025, at 3:30 p.m. GMT

Where relevant, the presentations will be webcast live and can be accessed by visiting ‘Events & Presentations’, under ‘Events’, via the ‘Investors’ section of Immunocore’s website at www.immunocore.com. Following the event, a replay of the presentations will be made available for a limited time.

About Immunocore

Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune diseases and infectious diseases. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including numerous active clinical and pre-clinical programs​ in oncology, infectious diseases, and autoimmune diseases. The Company’s most advanced oncology TCR therapeutic, KIMMTRAK, has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.

Contact Information

Immunocore

Sébastien Desprez, VP Communications
T: +44 (0) 7458030732
E: sebastien.desprez@immunocore.com
Follow Immunocore on LinkedIn: @Immunocore

Investor Relations

Clayton Robertson / Morgan Warenius
T: +1 (215) 384-4781
E: ir@immunocore.com

FAQ

When will Immunocore (IMCR) present at the Guggenheim Healthcare Innovation Conference?

Immunocore will present on Tuesday, November 11, 2025 at 3:00 p.m. EST.

What time is Immunocore (IMCR) scheduled for the Jefferies London Healthcare Conference?

The Jefferies fireside chat is scheduled for Wednesday, November 19, 2025 at 3:30 p.m. GMT.

Where can investors watch the Immunocore (IMCR) live webcasts for November 2025 presentations?

Live webcasts will be available via Investors > Events & Presentations on Immunocore's website at www.immunocore.com.

Will Immunocore (IMCR) post replays of the November 2025 conference presentations?

Yes, replays will be posted after each event and will be available for a limited time on the company's investor site.

Are the November 2025 Immunocore (IMCR) conference sessions investor-focused or technical?

These are investor-focused fireside chats where management presents company developments and answers investor questions.

How can I find the exact webcast link for Immunocore (IMCR) November 2025 events?

Visit www.immunocore.com and navigate to Investors > Events & Presentations for live links and replay access.